Skip to Main Content

The IBM Watson Health brand comes with baggage. But for its new owners, the core assets of the once-vaunted artificial intelligence outfit are the primary selling point for a new business to help clients acquire, process, and use patient data.

Now, they’ve unveiled the company’s new name: Merative. The rebranding aligns with the closing last week of IBM Watson Health’s sale to San Francisco-based private equity firm Francisco Partners. Merative, which bills itself as “a data, analytics and technology partner for the health industry,” will offer products that include imaging and clinical decision support software previously sold by Watson Health. Gerry McCarthy, former CEO of health care IT company eSolutions and president of Transunion Healthcare, will step into the CEO role.


At the time of the deal’s announcement in January, the firm hadn’t shared its plans for Watson Health’s assets, which included a national repository of data on insurance claims, medical images, and other patient data. But the firm’s other acquisitions pointed to something like what Merative is now selling: products for clinical decision support, clinical development, enterprise imaging, health care analytics, social program management, and real-world evidence. In December 2021, Francisco Partners purchased a health IT company that supports the exchange of claims data.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.